DURHAM, UK and CAMBRIDGE, UK, March 14, 2024 (Globe Newswire) — SM Discovery Group (SMDG), a preclinical-stage company developing treatments for neurodegenerative and rare pediatric diseases, today announced that Dr. announced the appointment of Devecseri, MD, MBA, elected to the Board of Directors. Dr. Devecseri is a highly successful executive in a biopharmaceutical business and brings extensive leadership experience to his SMDG as the company moves toward a critical period of R&D growth and expansion. .
“We are pleased to welcome Zuzanna, Global Head of Medical Affairs and Oncology at Novartis, to our Board of Directors,” said Shadi Farhangraj, Chief Executive Officer and Chairman of the Board of SMDG. said. “Zuzsanna is not only an extraordinary leader, but also a passionate physician and scientist. She has worked tirelessly through leadership positions, first as a pediatrician, then at Abbott, Sanofi, Genzyme, and now Novartis. , has dedicated her life to providing life-saving treatments to patients, and I know she brings a passion for helping patients and great pharmaceutical expertise and advice to SMDG. and our team share a common vision of bringing innovative treatments to patients.”
Dr. Devecseri added: My passion for lifesaving therapy has been a driving force throughout my professional career. SMDG's combination of vision, scientific knowledge, technical capabilities and outstanding talent is exciting and deeply engaging. I look forward to working closely with SMDG's outstanding team, CEO, and Board of Directors to support the company's continued growth and advance the company's mission and vision. ”
Dr. Devecseri began his career as a pediatric oncologist after graduating from Semmelweis Medical University in Hungary. He then earned his MBA in Economics from Corvinus University and a certificate in Health Economics and Outcomes Research from the University of Washington in Seattle. Dr. Devecseri holds certifications in health insurance and marketing excellence and is a certified coach. She began her career in the pharmaceutical industry in 2003 and has held increasing responsibilities across multiple therapeutic areas including cardiometabolic, oncology, and rare diseases at Abbott, Sanofi, Genzyme, and most recently Novartis. While working in various commercial and medical roles. Dr. Devecseri has had the opportunity to build and lead high-performing, dedicated teams, and she has developed a deep understanding of global health systems.
About SM Discovery Group (SMDG)
SMDG is a preclinical-stage biotechnology company focused on developing transformative, life-saving, first-in-class treatments for neurodegenerative and rare pediatric diseases. The company has conducted extensive preclinical studies demonstrating the outstanding capabilities and unprecedented safety of SMDG's therapeutic platforms, NanoLigand Carriers™ (NLC™) and NanoLigand Blocks™ (NLB™), and In particular, we demonstrated that it is possible to provide nucleic acid therapeutics for gene therapy across the blood-brain barrier. barrier. The SMDG treatment library was invented by Professor Moin Moghimi of the University of Newcastle and the University of Colorado Anschutz Medical Center.
For more information, please visit: www.smdiscovery.com
Media and Investor Contact:
admin@smdiscovery.com
